Results of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM)
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2018-10, Vol.29, p.viii122-viii123 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | viii123 |
|---|---|
| container_issue | |
| container_start_page | viii122 |
| container_title | Annals of oncology |
| container_volume | 29 |
| creator | Peereboom, D. Nabors, L.B. Kumthekar, P. Badruddoja, M. Fink, K. Lieberman, F. Phuphanich, S. Dunbar, E. Walbert, T. Schiff, D. Tran, D.D. Ashby, L.S. Butowski, N. Iwamoto, F. Lindsay, R. Bullington, J. Schulder, M. Sherman, J. Brooks, C. Reardon, D. |
| description | |
| doi_str_mv | 10.1093/annonc/mdy273.361 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdy273_361</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753419487905</els_id><sourcerecordid>S0923753419487905</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2781-bdbc71d43d08d09c828f55963569b53b1c17ddb7be792e1388d8c1db0a51240a3</originalsourceid><addsrcrecordid>eNp9kFtrGzEQhUVJaZy0P6AvQY8peBON5L2RJyfkYnAppO3zosvYVtiVFknr4t-SP5tNtuljnw4M55yZ-Qj5CuwCWC0upXPe6cvOHHgpLkQBH8gM8qLOKraAIzJjNRdZmYvFMTmJ8YkxVtS8_kSOBYfRXcCMPD9iHNoUqd_Qficj0tWKpmBl-zr5uc5KBnMqqfN7bKntusH5tMMg-wNNMmwxWbelq3UG4lHyOb3td8tRpDM0DmFv99bNqXVUmrctf2za0YjaO5O11iENqIcQ0CW6ba1XrYzJd5Ke319___aZfNzINuKXv3pKft_d_rp5yNY_7lc3y3WmeVlBpozSJZiFMKwyrNYVrzZ5XhdiJKFyoUBDaYwqFZY1RxBVZSoNRjGZA18wKU4JTL06-BgDbpo-2E6GQwOseQXdTKCbCXQzohszZ1OmH1SH5l_inexouJoMOF6-txiaqC06jcaOP6fGePuf-hdLmpBK</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Results of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM)</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Peereboom, D. ; Nabors, L.B. ; Kumthekar, P. ; Badruddoja, M. ; Fink, K. ; Lieberman, F. ; Phuphanich, S. ; Dunbar, E. ; Walbert, T. ; Schiff, D. ; Tran, D.D. ; Ashby, L.S. ; Butowski, N. ; Iwamoto, F. ; Lindsay, R. ; Bullington, J. ; Schulder, M. ; Sherman, J. ; Brooks, C. ; Reardon, D.</creator><creatorcontrib>Peereboom, D. ; Nabors, L.B. ; Kumthekar, P. ; Badruddoja, M. ; Fink, K. ; Lieberman, F. ; Phuphanich, S. ; Dunbar, E. ; Walbert, T. ; Schiff, D. ; Tran, D.D. ; Ashby, L.S. ; Butowski, N. ; Iwamoto, F. ; Lindsay, R. ; Bullington, J. ; Schulder, M. ; Sherman, J. ; Brooks, C. ; Reardon, D.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdy273.361</identifier><identifier>PMID: 32136161</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><ispartof>Annals of oncology, 2018-10, Vol.29, p.viii122-viii123</ispartof><rights>2018 THE AUTHORS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2781-bdbc71d43d08d09c828f55963569b53b1c17ddb7be792e1388d8c1db0a51240a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32136161$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Peereboom, D.</creatorcontrib><creatorcontrib>Nabors, L.B.</creatorcontrib><creatorcontrib>Kumthekar, P.</creatorcontrib><creatorcontrib>Badruddoja, M.</creatorcontrib><creatorcontrib>Fink, K.</creatorcontrib><creatorcontrib>Lieberman, F.</creatorcontrib><creatorcontrib>Phuphanich, S.</creatorcontrib><creatorcontrib>Dunbar, E.</creatorcontrib><creatorcontrib>Walbert, T.</creatorcontrib><creatorcontrib>Schiff, D.</creatorcontrib><creatorcontrib>Tran, D.D.</creatorcontrib><creatorcontrib>Ashby, L.S.</creatorcontrib><creatorcontrib>Butowski, N.</creatorcontrib><creatorcontrib>Iwamoto, F.</creatorcontrib><creatorcontrib>Lindsay, R.</creatorcontrib><creatorcontrib>Bullington, J.</creatorcontrib><creatorcontrib>Schulder, M.</creatorcontrib><creatorcontrib>Sherman, J.</creatorcontrib><creatorcontrib>Brooks, C.</creatorcontrib><creatorcontrib>Reardon, D.</creatorcontrib><title>Results of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM)</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kFtrGzEQhUVJaZy0P6AvQY8peBON5L2RJyfkYnAppO3zosvYVtiVFknr4t-SP5tNtuljnw4M55yZ-Qj5CuwCWC0upXPe6cvOHHgpLkQBH8gM8qLOKraAIzJjNRdZmYvFMTmJ8YkxVtS8_kSOBYfRXcCMPD9iHNoUqd_Qficj0tWKpmBl-zr5uc5KBnMqqfN7bKntusH5tMMg-wNNMmwxWbelq3UG4lHyOb3td8tRpDM0DmFv99bNqXVUmrctf2za0YjaO5O11iENqIcQ0CW6ba1XrYzJd5Ke319___aZfNzINuKXv3pKft_d_rp5yNY_7lc3y3WmeVlBpozSJZiFMKwyrNYVrzZ5XhdiJKFyoUBDaYwqFZY1RxBVZSoNRjGZA18wKU4JTL06-BgDbpo-2E6GQwOseQXdTKCbCXQzohszZ1OmH1SH5l_inexouJoMOF6-txiaqC06jcaOP6fGePuf-hdLmpBK</recordid><startdate>201810</startdate><enddate>201810</enddate><creator>Peereboom, D.</creator><creator>Nabors, L.B.</creator><creator>Kumthekar, P.</creator><creator>Badruddoja, M.</creator><creator>Fink, K.</creator><creator>Lieberman, F.</creator><creator>Phuphanich, S.</creator><creator>Dunbar, E.</creator><creator>Walbert, T.</creator><creator>Schiff, D.</creator><creator>Tran, D.D.</creator><creator>Ashby, L.S.</creator><creator>Butowski, N.</creator><creator>Iwamoto, F.</creator><creator>Lindsay, R.</creator><creator>Bullington, J.</creator><creator>Schulder, M.</creator><creator>Sherman, J.</creator><creator>Brooks, C.</creator><creator>Reardon, D.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201810</creationdate><title>Results of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM)</title><author>Peereboom, D. ; Nabors, L.B. ; Kumthekar, P. ; Badruddoja, M. ; Fink, K. ; Lieberman, F. ; Phuphanich, S. ; Dunbar, E. ; Walbert, T. ; Schiff, D. ; Tran, D.D. ; Ashby, L.S. ; Butowski, N. ; Iwamoto, F. ; Lindsay, R. ; Bullington, J. ; Schulder, M. ; Sherman, J. ; Brooks, C. ; Reardon, D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2781-bdbc71d43d08d09c828f55963569b53b1c17ddb7be792e1388d8c1db0a51240a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Peereboom, D.</creatorcontrib><creatorcontrib>Nabors, L.B.</creatorcontrib><creatorcontrib>Kumthekar, P.</creatorcontrib><creatorcontrib>Badruddoja, M.</creatorcontrib><creatorcontrib>Fink, K.</creatorcontrib><creatorcontrib>Lieberman, F.</creatorcontrib><creatorcontrib>Phuphanich, S.</creatorcontrib><creatorcontrib>Dunbar, E.</creatorcontrib><creatorcontrib>Walbert, T.</creatorcontrib><creatorcontrib>Schiff, D.</creatorcontrib><creatorcontrib>Tran, D.D.</creatorcontrib><creatorcontrib>Ashby, L.S.</creatorcontrib><creatorcontrib>Butowski, N.</creatorcontrib><creatorcontrib>Iwamoto, F.</creatorcontrib><creatorcontrib>Lindsay, R.</creatorcontrib><creatorcontrib>Bullington, J.</creatorcontrib><creatorcontrib>Schulder, M.</creatorcontrib><creatorcontrib>Sherman, J.</creatorcontrib><creatorcontrib>Brooks, C.</creatorcontrib><creatorcontrib>Reardon, D.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Peereboom, D.</au><au>Nabors, L.B.</au><au>Kumthekar, P.</au><au>Badruddoja, M.</au><au>Fink, K.</au><au>Lieberman, F.</au><au>Phuphanich, S.</au><au>Dunbar, E.</au><au>Walbert, T.</au><au>Schiff, D.</au><au>Tran, D.D.</au><au>Ashby, L.S.</au><au>Butowski, N.</au><au>Iwamoto, F.</au><au>Lindsay, R.</au><au>Bullington, J.</au><au>Schulder, M.</au><au>Sherman, J.</au><au>Brooks, C.</au><au>Reardon, D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Results of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM)</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2018-10</date><risdate>2018</risdate><volume>29</volume><spage>viii122</spage><epage>viii123</epage><pages>viii122-viii123</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><cop>England</cop><pub>Elsevier Ltd</pub><pmid>32136161</pmid><doi>10.1093/annonc/mdy273.361</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2018-10, Vol.29, p.viii122-viii123 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_annonc_mdy273_361 |
| source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| title | Results of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T00%3A52%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Results%20of%20phase%20II%20trial%20of%20SL-701,%20a%20novel%20immunotherapy%20targeting%20IL-13Ra2,%20EphA2,%20and%20survivin,%20in%20adults%20with%20second-line%20recurrent%20glioblastoma%20(GBM)&rft.jtitle=Annals%20of%20oncology&rft.au=Peereboom,%20D.&rft.date=2018-10&rft.volume=29&rft.spage=viii122&rft.epage=viii123&rft.pages=viii122-viii123&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdy273.361&rft_dat=%3Celsevier_cross%3ES0923753419487905%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32136161&rft_els_id=S0923753419487905&rfr_iscdi=true |